ArticleInternational journal of clinical oncology2026
Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGlofitamab is a T-cell engaging CD20xCD3 bispecific antibody approved for treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in the US and Europe.
methodsThis phase I study (jRCT2080225077) investigated safety, pharmacokinetics, and efficacy of glofitamab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). Patients received obinutuzumab pretreatment (1000 mg) 7 days before first glofitamab administration. Glofitamab was given with step-up dosing on Cycle (C)1 Day (D)1 and D8, then at target dose every 3 weeks from C2D1 (7 days after C1D8) (Cohort 1: 2.5/10/16 mg; Cohort 2: 2.5/10/30 mg) until progression. Primary endpoints were safety and pharmacokinetics; secondary endpoint was efficacy.
resultsEight patients with B-NHL (DLBCL, n = 5; follicular lymphoma [FL], n = 2; transformed FL, n = 1) were enrolled (Cohort 1, n = 5; Cohort 2, n = 3; median age, 64.5 years; Ann Arbor Stage III/IV, n = 7). The two patients with FL received no glofitamab due to hematological adverse events (AEs) after obinutuzumab. Median number of glofitamab cycles was 48 (Cohort 1) and 43 (Cohort 2). Seven patients had grade 3/4 AEs; no grade 5 AEs were reported. Two patients had serious AEs; no dose-limiting toxicities were observed. Cytokine release syndrome occurred in all glofitamab-treated patients (grade 1/2/3: n = 3/n = 2/n = 1), predominantly in C1. Serum glofitamab concentrations showed similar time profiles in both cohorts, and exposure increased in a dose-proportional manner. Overall and complete response rates were 75.0% (6/8 patients; Cohort 1: 3/5 patients [60.0%]; Cohort 2: 3/3 patients [100%]).
conclusionGlofitamab demonstrated a manageable safety profile with encouraging response rates in Japanese patients with relapsed/refractory B-NHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.